AbCellera Biologics (ABCL) Competitors

$6.47 +0.31 (+5.03%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$6.48 +0.01 (+0.22%)

As of 07/17/2026 07:59 PM Eastern

ABCL vs. APGE, IMVT, MIRM, RYTM, and PTCT

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include Apogee Therapeutics (APGE), Immunovant (IMVT), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does AbCellera Biologics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Apogee Therapeutics had 8 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Apogee Therapeutics and 0 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat Apogee Therapeutics' score of 0.87 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Positive
AbCellera Biologics	Very Positive

AbCellera Biologics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
AbCellera Biologics	$75.13M	26.30	-$146.41M	-$0.48	N/A

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Apogee Therapeutics presently has a consensus target price of $121.25, indicating a potential downside of 9.51%. AbCellera Biologics has a consensus target price of $8.00, indicating a potential upside of 23.65%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

AbCellera Biologics beats Apogee Therapeutics on 11 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Immunovant has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, Immunovant had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for Immunovant and 0 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat Immunovant's score of 0.66 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunovant	Positive
AbCellera Biologics	Very Positive

AbCellera Biologics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
AbCellera Biologics	$75.13M	26.30	-$146.41M	-$0.48	N/A

Immunovant presently has a consensus price target of $39.70, suggesting a potential downside of 1.39%. AbCellera Biologics has a consensus price target of $8.00, suggesting a potential upside of 23.65%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

47.1% of Immunovant shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

AbCellera Biologics beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Mirum Pharmaceuticals has a net margin of -140.24% compared to AbCellera Biologics' net margin of -181.75%. Mirum Pharmaceuticals' return on equity of -11.28% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AbCellera Biologics currently has a consensus target price of $8.00, suggesting a potential upside of 23.65%. Mirum Pharmaceuticals has a consensus target price of $143.40, suggesting a potential upside of 20.65%. Given AbCellera Biologics' higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

AbCellera Biologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	26.30	-$146.41M	-$0.48	N/A
Mirum Pharmaceuticals	$521.31M	13.90	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 5 mentions for Mirum Pharmaceuticals and 0 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat Mirum Pharmaceuticals' score of 1.32 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
AbCellera Biologics	Very Positive
Mirum Pharmaceuticals	Positive

Summary

Mirum Pharmaceuticals beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AbCellera Biologics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	26.30	-$146.41M	-$0.48	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

In the previous week, Rhythm Pharmaceuticals had 4 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 0 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat Rhythm Pharmaceuticals' score of 0.89 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
AbCellera Biologics	Very Positive
Rhythm Pharmaceuticals	Positive

AbCellera Biologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $8.00, suggesting a potential upside of 23.65%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 29.72%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Rhythm Pharmaceuticals has a net margin of -93.33% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

AbCellera Biologics beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to PTC Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

PTC Therapeutics has a net margin of -22.58% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

AbCellera Biologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than AbCellera Biologics. PTC Therapeutics is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	26.30	-$146.41M	-$0.48	N/A
PTC Therapeutics	$1.73B	3.77	$682.64M	-$2.33	N/A

AbCellera Biologics currently has a consensus target price of $8.00, suggesting a potential upside of 23.65%. PTC Therapeutics has a consensus target price of $92.43, suggesting a potential upside of 17.61%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

In the previous week, PTC Therapeutics had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 11 mentions for PTC Therapeutics and 0 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.89 beat PTC Therapeutics' score of 0.53 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
AbCellera Biologics	Very Positive
PTC Therapeutics	Positive

Summary

AbCellera Biologics beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.88B	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-13.48	20.85	27.14	23.89
Price / Sales	26.30	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	2.00	8.26	10.69	6.18
Net Income	-$146.41M	$23.83M	$3.59B	$331.73M
7 Day Performance	-4.85%	-3.48%	-2.18%	-2.09%
1 Month Performance	17.00%	2.58%	1.63%	-2.19%
1 Year Performance	44.42%	45.93%	25.56%	17.20%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.6245 of 5 stars	$6.47 +5.0%	$8.00 +23.6%	+65.9%	$1.88B	$75.13M	N/A	500	Positive News
APGE Apogee Therapeutics	1.8769 of 5 stars	$133.65 +0.1%	$121.25 -9.3%	+243.6%	$8.27B	N/A	N/A	91	Short Interest Decrease
IMVT Immunovant	1.7881 of 5 stars	$39.71 -3.4%	$39.70 0.0%	+120.2%	$8.15B	N/A	N/A	120	Gap Down
MIRM Mirum Pharmaceuticals	3.0672 of 5 stars	$122.13 -4.4%	$143.40 +17.4%	+125.4%	$7.45B	$521.31M	N/A	140
RYTM Rhythm Pharmaceuticals	2.796 of 5 stars	$108.40 -6.1%	$138.29 +27.6%	+17.6%	$7.43B	$189.76M	N/A	140	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. APGE, IMVT, MIRM, RYTM, and PTCT

How does AbCellera Biologics compare to Apogee Therapeutics?

Summary

How does AbCellera Biologics compare to Immunovant?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Summary

How does AbCellera Biologics compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. APGE, IMVT, MIRM, RYTM, and PTCT

How does AbCellera Biologics compare to Apogee Therapeutics?

Does the media favor APGE or ABCL?

Which has higher earnings and valuation, APGE or ABCL?

Do insiders & institutionals have more ownership in APGE or ABCL?

Is APGE or ABCL more profitable?

Which has more volatility & risk, APGE or ABCL?

Do analysts rate APGE or ABCL?

Summary

How does AbCellera Biologics compare to Immunovant?

Is IMVT or ABCL more profitable?

Which has more risk & volatility, IMVT or ABCL?

Does the media refer more to IMVT or ABCL?

Which has stronger valuation & earnings, IMVT or ABCL?

Do analysts prefer IMVT or ABCL?

Do insiders and institutionals have more ownership in IMVT or ABCL?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Is ABCL or MIRM more profitable?

Do institutionals & insiders have more ownership in ABCL or MIRM?

Do analysts prefer ABCL or MIRM?

Which has more volatility & risk, ABCL or MIRM?

Which has better valuation and earnings, ABCL or MIRM?

Does the media refer more to ABCL or MIRM?

Summary

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Do institutionals and insiders have more ownership in ABCL or RYTM?

Which has higher earnings & valuation, ABCL or RYTM?

Does the media refer more to ABCL or RYTM?

Which has more volatility and risk, ABCL or RYTM?

Do analysts prefer ABCL or RYTM?

Is ABCL or RYTM more profitable?

Summary

How does AbCellera Biologics compare to PTC Therapeutics?

Is ABCL or PTCT more profitable?

Which has more risk & volatility, ABCL or PTCT?

Do insiders and institutionals have more ownership in ABCL or PTCT?

Which has preferable valuation & earnings, ABCL or PTCT?

Do analysts prefer ABCL or PTCT?

Does the media prefer ABCL or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools